share_log

Earnings Call Summary | DLH Holdings(DLHC.US) Q2 2024 Earnings Conference

Earnings Call Summary | DLH Holdings(DLHC.US) Q2 2024 Earnings Conference

業績電話會議摘要 | DLH Holdings (DLHC.US) 2024 年第二季度業績發佈會
富途資訊 ·  05/04 16:27  · 電話會議

The following is a summary of the DLH Holdings Corporation (DLHC) Q2 2024 Earnings Call Transcript:

以下是DLH控股公司(DLHC)2024年第二季度業績電話會議記錄摘要:

Financial Performance:

財務業績:

  • DLH Holdings Corporation reported Q2 revenue of $101 million.

  • Company EBITDA stood at $10.2 million in the second quarter with operating cash generated at $5.2 million in the period, bringing the year-to-date total to over $10 million.

  • The firm reduced its debt by $3.6 million, finishing the period with $170.8 million of total debt remaining.

  • Expectations are for debt reduction between $153 million and $157 million by the end of the fiscal year.

  • DLH Holdings Corporation公佈的第二季度收入爲1.01億美元。

  • 公司第二季度息稅折舊攤銷前利潤爲1,020萬美元,同期產生的運營現金爲520萬美元,使今年迄今爲止的總額超過1000萬美元。

  • 該公司減少了360萬美元的債務,在此期間結束時還剩下1.708億美元的總債務。

  • 預計到本財年末,債務將減少1.53億美元至1.57億美元。

Business Progress:

業務進展:

  • During Q2, DLH increased its backlog by over $80 million to $736 million from the end of Q1.

  • The company won several awards during the period, including two vital recompetes, strengthening their standing in the National Institute of Health sector.

  • DLH continues investing and reshaping their portfolio through business development activities and responding to active pipeline opportunities.

  • The company's future plans focus on growth and expansion in digital transformation and cybersecurity, which are crucial for enhancing R&D.

  • Despite potential uncertainties, DLH expects continued growth throughout the year and beyond.

  • 在第二季度,自第一季度末以來,DLH的積壓量增加了8000多萬美元,達到7.36億美元。

  • 在此期間,該公司贏得了多個獎項,包括兩項重要的複賽,鞏固了他們在國立衛生研究院領域的地位。

  • DLH繼續通過業務發展活動進行投資和重組其投資組合,並應對活躍的管道機會。

  • 該公司的未來計劃側重於數字化轉型和網絡安全的增長和擴張,這對於加強研發至關重要。

  • 儘管存在潛在的不確定性,但DLH預計全年及以後將持續增長。

More details: DLH Holdings IR

更多詳情: DLH 控股投資者關係

Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.

提示:欲了解更多詳情,請訪問投資者關係網站。本文僅供投資者參考,不構成任何投資建議。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論